GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (STU:260) » Definitions » EBITDA Margin %

Centessa Pharmaceuticals (STU:260) EBITDA Margin % : 0.00% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Centessa Pharmaceuticals's EBITDA for the three months ended in Jun. 2024 was €-37.49 Mil. Centessa Pharmaceuticals's Revenue for the three months ended in Jun. 2024 was €0.00 Mil. Therefore, Centessa Pharmaceuticals's EBITDA margin for the quarter that ended in Jun. 2024 was 0.00%.


Centessa Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for Centessa Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals EBITDA Margin % Chart

Centessa Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
- - - - -2,413.99

Centessa Pharmaceuticals Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -479.76 - -

Competitive Comparison of Centessa Pharmaceuticals's EBITDA Margin %

For the Biotechnology subindustry, Centessa Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Centessa Pharmaceuticals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's EBITDA Margin % falls into.



Centessa Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Centessa Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-151.695/6.284
=-2,413.99 %

Centessa Pharmaceuticals's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-37.485/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centessa Pharmaceuticals  (STU:260) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Centessa Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Centessa Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Centessa Pharmaceuticals Headlines

No Headlines